reimbursement

Better U.S. Patient Access To Cancer Drugs Comes At A Price
Better U.S. Patient Access To Cancer Drugs Comes At A Price
Forbes
cancer
Europe
patient access
patients
reimbursement
drug pricing
Flag link:
Medicare sets outpatient rate for Yescarta reimbursement
Medicare sets outpatient rate for Yescarta reimbursement
Reuters
Medicare
Yescarta
reimbursement
Gilead Sciences
Flag link:
Medical device reimbursement: How it’s a brave new world
Medical device reimbursement: How it’s a brave new world
Medical Design and Outsourcing
devices
reimbursement
Flag link:
Reimbursement Trends for Medical Devices in Japan
Reimbursement Trends for Medical Devices in Japan
Medical Devices and Diagnostics Industry
devices
Japan
reimbursement
Flag link:
Medical Device Reimbursement in the US
Medical Device Reimbursement in the US
RAPS.org
devices
reimbursement
Flag link:
Remicade: A Case Study in How U.S. Pricing and Reimbursement Curb Adoption of Biosimilars
Remicade: A Case Study in How U.S. Pricing and Reimbursement Curb Adoption of Biosimilars
Drug Channels
drug pricing
reimbursement
Remicade
biosimilars
Janssen
Inflectra
Pfizer
Renflexis
Merck
Flag link:
Can Novartis' Kisqali beat Pfizer's market-leading Ibrance to reimbursement in England?
Can Novartis' Kisqali beat Pfizer's market-leading Ibrance to reimbursement in England?
Fierce Pharma
Novartis
Kisqali
Pfizer
Ibrance
reimbursement
breast cancer
Flag link:
Why regional reimbursement strategies could be right for medtech
Why regional reimbursement strategies could be right for medtech
Medical Design and Outsourcing
devices
reimbursement
CMS
Flag link:
5 hurdles facing biosimilar developers
5 hurdles facing biosimilar developers
BioPharma Dive
biosimilars
drug development
drug pricing
legal issues
reimbursement
drug manufacturing
Flag link:
Is Amgen still shooting blanks in its war with payers over Repatha reimbursement?
Is Amgen still shooting blanks in its war with payers over Repatha reimbursement?
Endpoints
Amgen
Repatha
payers
reimbursement
Flag link:
Reimbursement rather than Brexit more likely to impact how drugmakers order global launches
Reimbursement rather than Brexit more likely to impact how drugmakers order global launches
Medical Marketing and Media
drug launches
global launches
Brexit
reimbursement
Flag link:
Are US reimbursement trends stifling medical device innovation?
Are US reimbursement trends stifling medical device innovation?
Mass Device
devices
reimbursement
innovation
GPOs
Flag link:
Why Gathering Health Economic Data for Cancer Drugs is Now Essential
Why Gathering Health Economic Data for Cancer Drugs is Now Essential
Medical Marketing and Media
oncology
health economics
reimbursement
Flag link:
A proposal for biosimilar reimbursement sparks outrage
A proposal for biosimilar reimbursement sparks outrage
Pharmalot
biosimilars
CMS
reimbursement
Flag link:
What's worrying pharma? Reimbursement, yes, but also M&A, global threats, and the economy
What's worrying pharma? Reimbursement, yes, but also M&A, global threats, and the economy
Fierce Pharma
M&A
reimbursement
Flag link:
Is this MannKind Corporation's Worst Nightmare?
Is this MannKind Corporation's Worst Nightmare?
Motley Fool
MannKind
Afrezza
diabetes
reimbursement
Flag link:
Will Orphan Drug Reimbursement Policies Remain Stable?
Will Orphan Drug Reimbursement Policies Remain Stable?
Pharmalot
orphan drugs
reimbursement
Flag link:
Biogen's impressive Tecfidera launch hits reimbursement, supply snags
Biogen's impressive Tecfidera launch hits reimbursement, supply snags
Fierce Pharma
Biogen Idec
Tecfidera
reimbursement
MS
multiple sclerosis
drug launches
Flag link:
Many Biotechs Fail To Embrace Reimbursement Issues
Many Biotechs Fail To Embrace Reimbursement Issues
Pharmalot
biotech
reimbursement
Flag link:
Reimbursement battle for Qsymia hits Vivus figures
Reimbursement battle for Qsymia hits Vivus figures
Pharma Times, UK
Vivus
reimbursement
Qsymia
Flag link:

Pages